1. Scrip
  2. >>Business

Alnylam Confident It Won’t Stumble On ATTR Trial Like BridgeBio

Aiming To Challenge Pfizer In Cardiomyopathy

 
• By Andrew McConaghie

Alnylam expects success in its Phase III study in amyloid cardiomyopathy- but a competitor’s baffling failure is making analysts jittery.

Alnylam building
Alnylam is depending on the trial to expand into treating ATTR cardiomyopathy patients. • Source: Alamy

Alnylam is awaiting a pivotal trial readout from Onpattro (patisiran) which should help extend its presence in rare disease transthyretin amyloidosis (ATTR), but analysts are wary after the failure of a similar study by a competitor.

Last month BridgeBio Pharma’s candidate acoramidis failed to show improvements in ATTR patients with heart condition amyloid cardiomyopathy (ATTR-CM) in completing a six minute walk test

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

UK-India FTA Could Offer ‘Significant Benefits’ For Generics, Biosimilars

 
• By Dave Wallace

A free trade agreement between the UK and India could offer “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments.

Will Other Major MASH Deals Follow GSK/Boston Pharma?

 
• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers

 
• By Alaric DeArment

The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.